ADLM 2025 Recordings - now available for purchase
Access more than 100 hours of the conference's popular and timely sessions presented at ADLM 2025. Recordings will be available for viewing through July 31, 2026.
AACC’S Disruptive Technology Award Competition 2019
(This should be listed on the main page, replacing the “Award Details”, which can now be removed)
Congratulations to all of AACC’s 2019 Disruptive Technology Award Semi-Finalists
Bacteromic (link this to www.bacteromic.com)
Bacteromic provides broadband automated antimicrobial susceptibility testing (AST) in any CLIA moderately complex laboratory, yielding unprecedented information capacity for up to 60 random-access samples in parallel, at the cost of standard automated AST.
COMBiNATi (link this to https://www.combinati.com/)
COMBiNATi is digital PCR reimagined - single instrument, ultralow sample waste, fast time-to-result, and unparalleled multiplexity.
Inflammatix (link this to www.inflammatix.com)
Inflammatix is a molecular diagnostics company developing rapid tests that read the immune system, focused on developing tests for acute infections and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University.
Newomics (link this to www.newomics.com)
Newomics Inc. presents a direct and rapid quantitation of intact proteins in human plasma by LC-MS (without IP and trypsin digestion).
PCR ONE (link this to www.pcrone.com)
The PCR|ONE system is a fully automated, multiplexed PCR system for sample preparation, amplification, and detection of DNA in 15 minutes—a true “sample-in-answer-out” technology for rapid point-of-care diagnostics of infections.
PixCell Medical Technologies (link this to https://www.pixcell-medical.com/)
PixCell's disruptive lab-on-cartridge technology offers a paradigm shift in healthcare by simplifying blood tests and making high-end advanced diagnostics accessible at the Point-Of-Care (POC), thus enabling the widespread early detection of cancer, heart failure, and infection.
Singlera Genomics (link this to https://singleraoncology.com/assays/)
Singlera Genomics ColonES test uses NGS-based targeted methylation haplotyping of bisulfite-treated cell-free DNA for early colorectal cancer screening.
Special thanks to the following experts for their valuable time and feedback during the execution and planning of this event:
And THANK YOU to all the applicants who submitted their technology to this competition. We wish you All the Best and invite you to apply to other events like this in the future.